Prascend 160 tabs

Boehringer Ingelheim
Expiry date:
Pergolide tablet for treatment of PPID
More info

60 Prascend Tablets. Each Prascend tablet contains 1.0 mg pergolide (as pergolide mesylate 1.31 mg).

Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) (Equine Cushing’s Disease).

Do not use in horses with known hypersensitivity to pergolide mesylate or other ergot derivatives.
Do not use in horses less than 2 years of age.
Do not use in horses intended for human consumption.

Potential adverse reactions in horses include sweating, inappetence, transient anorexia and lethargy, mild central nervous system signs (e.g. mild depression and mild ataxia), diarrhoea and colic. If signs of dose intolerance develop, treatment should be stopped for 2 to 3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.5 mg increments every 2 to 4 weeks.

Dosage and administration:
The product should be administered orally, once daily.
The starting dose is 2 µg/kg. The recommended doses are as follows:
200 - 400 kg of body weight:      1/2 tablet
401 - 600 kg of body weight:      1 tablet
601 - 850 kg of body weight:      1 1/2 tablets
851 - 1000 kg of body weight:    2 tablets

More Information
Nr. 60130
Registration number REG NL 110598
Brand Boehringer Ingelheim
Chilled No
Active Ingredient Pergolide
Target species Horse
Legal status of supply UDA
Route of administration Oral
Withdrawal period Do not use in animals intended for human consumption.
Batch 9E9758
Expiry date Dec 31, 2021
Units per outer box 0
Ingredients 1.0 mg pergolide/ tablet (as pergolide mesylate 1.31 mg)
© 2020 Grovet B.V. All rights reserved.